Cytheris expands interleukin trials for hepatitis C
This article was originally published in Scrip
Executive Summary
Cytheris has begun an additional clinical trial with its main pipeline project CYT107, this time looking at the glycosylated recombinant human interleukin-7 molecule as add-on immunotherapy for chronic hepatitis C virus (HCV) patients unresponsive to standard combination treatment.